MCID: ADN011
MIFTS: 71

Adenoid Cystic Carcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Neuronal diseases, Oral diseases, Rare diseases, Skin diseases

Aliases & Classifications for Adenoid Cystic Carcinoma

MalaCards integrated aliases for Adenoid Cystic Carcinoma:

Name: Adenoid Cystic Carcinoma 12 12 75 53 6 15 17 72
Salivary Gland Adenoid Cystic Carcinoma 12 55 15
Cylindroma 12 53
Adenoid Cystic Carcinoma of Salivary Gland 72
Carcinoma, Adenoid Cystic 44
Eccrine Dermal Cylindroma 72
Carcinoma Adenoid Cystic 55
Adenoid Cystic Cancer 12
Adenocystic Carcinoma 53
Carcinoma, Cribriform 72
Cribriform Carcinoma 53

Classifications:



External Ids:

Disease Ontology 12 DOID:0080202 DOID:4866
MeSH 44 D003528
NCIt 50 C2970
SNOMED-CT 68 11671000
UMLS 72 C0010606 C0205643 C0279751 more

Summaries for Adenoid Cystic Carcinoma

NIH Rare Diseases : 53 Adenoid cystic carcinoma (ACC) is a rare form of adenocarcinoma, a type of cancer that begins in glandular tissues. It most commonly arises in the major and minor salivary glands of the head and neck. It can also occur in the breast, uterus, or other locations in the body. Symptoms depend on the tumor's location. Salivary gland tumors may cause painless masses in the mouth or face. Tumors of the lacrimal gland may cause a bulging eye or changes in vision. Those affecting the windpipe or voice box may cause respiratory symptoms or changes in speech, respectively. Advanced tumors may cause pain and/or nerve paralysis, as ACC often spreads along the nerves. It may also spread through the bloodstream. It spreads to the lymph nodes in about 5% to 10% of cases. The cause of ACC is currently unknown. It typically does not run in families. Treatment depends on many factors and may include surgery, radiation, and/or chemotherapy. Unfortunately, ACC is typically an aggressive form of cancer that has a poor long-term outlook.

MalaCards based summary : Adenoid Cystic Carcinoma, also known as salivary gland adenoid cystic carcinoma, is related to breast adenoid cystic carcinoma and lung adenoid cystic carcinoma, and has symptoms including pain An important gene associated with Adenoid Cystic Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Miconazole and Promethazine have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, breast and lung, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An adenocarcinoma that is characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells.

Wikipedia : 75 Adenoid cystic carcinoma is a rare type of cancer that can exist in many different body sites. This... more...

Related Diseases for Adenoid Cystic Carcinoma

Diseases related to Adenoid Cystic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 544)
# Related Disease Score Top Affiliating Genes
1 breast adenoid cystic carcinoma 35.5 NFIB KIT ERBB2
2 lung adenoid cystic carcinoma 35.4 PIK3CA NFIB KRAS KIT HRAS
3 prostate adenoid cystic carcinoma 35.2 PIK3CA HRAS
4 prostate cancer 33.2 TP53 SERPINA3 PTEN PIK3CA KRAS HRAS
5 pleomorphic adenoma 32.6 TP53 KRT14 ERBB2
6 polymorphous low-grade adenocarcinoma 32.5 NFIB MYB KIT CCND1
7 adenocarcinoma 32.2 TP53 PTEN PIK3CA KRAS KIT HRAS
8 squamous cell carcinoma 31.9 TP53 PTEN PIK3CA NOTCH1 HRAS ERBB2
9 in situ carcinoma 31.8 TP53 KRT14 ERBB2
10 small cell carcinoma 31.7 TP53 SMARCA2 PTEN KRT7 KIT
11 nasopharyngeal carcinoma 31.7 TP53 PIK3CA HRAS CCND1 AKT1
12 mucoepidermoid carcinoma 31.7 KRT7 KRT14 ERBB2
13 exanthem 31.7 KRAS HRAS ERBB2
14 basaloid squamous cell carcinoma 31.7 TP53 KRT7 KRT14
15 squamous cell carcinoma, head and neck 31.6 TP53 PTEN PIK3CA HRAS ERBB2 CCND1
16 epithelial-myoepithelial carcinoma 31.6 TP53 KRT7 KRT14 HRAS FBXW7
17 esophageal cancer 31.5 TP53 PTEN PIK3CA KRAS HRAS ERBB2
18 papilloma 31.5 TP53 PTEN KRT7 KRT14 CCND1
19 apocrine adenoma 31.5 PIK3CA KRAS HRAS
20 ductal carcinoma in situ 31.4 TP53 KRT14 ERBB2 CCND1 AKT1
21 thymoma, familial 31.3 KIT HRAS
22 necrotizing sialometaplasia 31.3 TP53 KRT7 KIT
23 tongue cancer 31.3 TP53 NOTCH1 CCND1
24 thymoma 31.3 TP53 KIT HRAS AKT1
25 cervical adenocarcinoma 31.3 TP53 KRT7 ERBB2
26 myeloid leukemia 31.3 TP53 KIT IDH1 HRAS
27 bladder cancer 31.2 TP53 KRAS HRAS ERBB2 CCND1
28 suppression of tumorigenicity 12 31.2 TP53 PTEN PIK3CA IDH1 HRAS AKT1
29 lung squamous cell carcinoma 31.2 TP53 PTEN PIK3CA KRAS HRAS AKT1
30 breast cancer 31.2 TP53 PTEN PIK3CA NOTCH1 KRT14 KRAS
31 malignant spiradenoma 31.2 TP53 PIK3CA KRT7
32 cervical cancer 31.2 TP53 PTEN PIK3CA NOTCH1 KRT14 HRAS
33 gastric cancer 31.2 TP53 PTEN PIK3CA KRAS ERBB2 CCND1
34 glioma 31.2 TP53 PTEN PIK3CA IDH1 ERBB2 CCND1
35 gastrointestinal stromal tumor 31.1 TP53 PTEN KRAS KIT CCND1 AKT1
36 hidradenoma 31.1 PIK3CA KRT7 AKT1
37 glioblastoma multiforme 31.1 TP53 PTEN PIK3CA IDH1 ERBB2 CCND1
38 differentiated thyroid carcinoma 31.1 TP53 KRAS HRAS
39 gliosarcoma 31.1 TP53 PTEN IDH1
40 lymphoma, non-hodgkin, familial 31.1 TP53 PIK3CA NOTCH1 CCND1
41 lung benign neoplasm 31.0 TP53 KRT7 KRAS HRAS
42 lung cancer susceptibility 3 31.0 TP53 PIK3CA KRT7 KRAS IDH1 HRAS
43 transitional cell carcinoma 31.0 TP53 PTEN KRT7 HRAS ERBB2
44 glioblastoma 31.0 TP53 PTEN PIK3CA IDH1 HRAS ERBB2
45 breast ductal carcinoma 31.0 TP53 ERBB2 CCND1
46 pancreatic cancer 31.0 TP53 PIK3CA KRAS HRAS ERBB2 CCND1
47 ceruminoma 31.0 KRT7 KIT
48 carcinosarcoma 31.0 TP53 PTEN PIK3CA KRT7 KRAS KIT
49 sweat gland cancer 31.0 TP53 KRT7 KRT14 ERBB2
50 merkel cell carcinoma 30.9 TP53 KRT7 KIT

Graphical network of the top 20 diseases related to Adenoid Cystic Carcinoma:



Diseases related to Adenoid Cystic Carcinoma

Symptoms & Phenotypes for Adenoid Cystic Carcinoma

UMLS symptoms related to Adenoid Cystic Carcinoma:


pain

GenomeRNAi Phenotypes related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.7 HRAS KRAS PIK3CA
2 Decreased viability GR00106-A-0 10.7 KRAS
3 Decreased viability GR00221-A-1 10.7 AKT1 CYLD HRAS KRAS PIK3CA KIT
4 Decreased viability GR00221-A-2 10.7 AKT1 CYLD HRAS KRAS PIK3CA
5 Decreased viability GR00221-A-3 10.7 AKT1 HRAS
6 Decreased viability GR00221-A-4 10.7 AKT1 PIK3CA
7 Decreased viability GR00301-A 10.7 CYLD KRAS KIT
8 Decreased viability GR00381-A-1 10.7 KRAS
9 Decreased viability GR00402-S-2 10.7 AKT1 CYLD HRAS KRAS PIK3CA KIT
10 Decreased viability in esophageal squamous lineage GR00235-A 9.97 CCND1 ERBB2 HRAS IDH1 JAK3 KIT
11 Increased cell death HMECs cells GR00103-A-0 9.43 CYLD FBXW7 PIK3CA PTEN SMARCA2 TP53
12 Reduced mammosphere formation GR00396-S 9.17 CCND1 HRAS JAK3 KRAS KRT7 NOTCH1

MGI Mouse Phenotypes related to Adenoid Cystic Carcinoma:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.51 AKT1 CCND1 CYLD ERBB2 FBXW7 JAK3
2 endocrine/exocrine gland MP:0005379 10.51 AKT1 CCND1 CYLD ERBB2 FBXW7 HRAS
3 growth/size/body region MP:0005378 10.5 AKT1 CCND1 CYLD ERBB2 FBXW7 HRAS
4 homeostasis/metabolism MP:0005376 10.48 AKT1 CCND1 CYLD ERBB2 FBXW7 HRAS
5 mortality/aging MP:0010768 10.45 AKT1 CCND1 CYLD ERBB2 FBXW7 HRAS
6 digestive/alimentary MP:0005381 10.44 CCND1 CYLD ERBB2 FBXW7 HRAS JAK3
7 integument MP:0010771 10.4 AKT1 CCND1 CYLD ERBB2 FBXW7 HRAS
8 cardiovascular system MP:0005385 10.39 AKT1 CCND1 ERBB2 FBXW7 HRAS KIT
9 immune system MP:0005387 10.38 AKT1 CCND1 CYLD FBXW7 IDH1 JAK3
10 hematopoietic system MP:0005397 10.37 AKT1 CCND1 CYLD FBXW7 IDH1 JAK3
11 craniofacial MP:0005382 10.3 CCND1 ERBB2 FBXW7 HRAS KIT KRAS
12 neoplasm MP:0002006 10.3 AKT1 CCND1 CYLD ERBB2 FBXW7 HRAS
13 embryo MP:0005380 10.28 AKT1 ERBB2 FBXW7 KIT KRAS MYB
14 nervous system MP:0003631 10.21 AKT1 CCND1 ERBB2 FBXW7 HRAS KIT
15 normal MP:0002873 10.18 AKT1 CCND1 CYLD ERBB2 FBXW7 HRAS
16 muscle MP:0005369 10.13 AKT1 ERBB2 KIT KRAS NOTCH1 PIK3CA
17 liver/biliary system MP:0005370 10.11 AKT1 FBXW7 KIT KRAS MYB NOTCH1
18 respiratory system MP:0005388 10 AKT1 CCND1 CYLD ERBB2 FBXW7 HRAS
19 reproductive system MP:0005389 9.96 AKT1 CCND1 ERBB2 KIT KRAS KRT14
20 renal/urinary system MP:0005367 9.92 HRAS KIT KRAS KRT7 NOTCH1 PTEN
21 pigmentation MP:0001186 9.85 KIT KRAS KRT14 NOTCH1 PTEN TP53
22 skeleton MP:0005390 9.73 AKT1 CCND1 ERBB2 HRAS IDH1 KIT
23 vision/eye MP:0005391 9.32 CCND1 FBXW7 KIT KRAS KRT14 NFIB

Drugs & Therapeutics for Adenoid Cystic Carcinoma

Drugs for Adenoid Cystic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
2
Promethazine Approved, Investigational Phase 3 60-87-7 4927
3
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
4
Histamine Approved, Investigational Phase 3 51-45-6 774
5
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Cevimeline Approved Phase 3 107233-08-9 25137844 83898
8
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
9
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
10 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
11 Porfiromycin Investigational Phase 3 801-52-5
12 Anti-Infective Agents Phase 2, Phase 3
13 Antifungal Agents Phase 2, Phase 3
14 Anti-Bacterial Agents Phase 3
15 Antibiotics, Antitubercular Phase 3
16 Neurotransmitter Agents Phase 3
17 Antidepressive Agents Phase 3
18 Hypnotics and Sedatives Phase 3
19 Histamine Antagonists Phase 3
20 Central Nervous System Depressants Phase 3
21
Histamine Phosphate Phase 3 51-74-1 65513
22 Psychotropic Drugs Phase 3
23 Antidepressive Agents, Tricyclic Phase 3
24 Alkylating Agents Phase 3
25 Liver Extracts Phase 3
26 Analgesics Phase 3
27 Anesthetics, Intravenous Phase 3
28 Narcotics Phase 3
29 Peripheral Nervous System Agents Phase 3
30 Analgesics, Opioid Phase 3
31 Adjuvants, Anesthesia Phase 3
32 Anesthetics, General Phase 3
33 Anesthetics Phase 3
34 Nucleic Acid Synthesis Inhibitors Phase 3
35 Mitomycins Phase 3
36 Cholinergic Agents Phase 3
37 Muscarinic Agonists Phase 3
38 Autonomic Agents Phase 3
39 14-alpha Demethylase Inhibitors Phase 2, Phase 3
40 Cytochrome P-450 CYP2C9 Inhibitors Phase 2, Phase 3
41 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
42 Steroid Synthesis Inhibitors Phase 2, Phase 3
43 Hormone Antagonists Phase 2, Phase 3
44 Cytochrome P-450 CYP2C19 Inhibitors Phase 2, Phase 3
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
46 Contraceptives, Oral Phase 3
47 Contraceptive Agents Phase 3
48 Central Nervous System Stimulants Phase 3
49 Antineoplastic Agents, Hormonal Phase 3
50 Appetite Stimulants Phase 3

Interventional clinical trials:

(show top 50) (show all 117)
# Name Status NCT ID Phase Drugs
1 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
2 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 RADIATION WITH MITOMYCIN C OR PORFIROMYCIN IN THE TREATMENT OF CANCER OF THE HEAD AND NECK AREA Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
4 Role of Peri-operative Immunonutrition in Cancers of the Higher Aero-digestive Tract Completed NCT00765440 Phase 3
5 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region Completed NCT00017511 Phase 3 cevimeline hydrochloride
6 A PHASE II/III PILOT STUDY OF THE EFFECTS OF PROPHYLACTIC FLUCONAZOLE THERAPY ON MUCOSITIS IN PATIENTS UNDERGOING RADIATION TREATMENT FOR HEAD AND NECK CANCER Completed NCT00002533 Phase 2, Phase 3 fluconazole
7 A Phase III, Double-Blind, Randomized Study Of The Effect Of Megestrol Acetate On Weight And Health Related Quality Of Life In Head And Neck Cancer Patients Receiving Radiation Therapy Completed NCT00006799 Phase 3 megestrol acetate
8 Acupuncture for Pain and Dysfunction Following Neck Dissection: A Randomized, Controlled, Phase III Trial Completed NCT00090337 Phase 3
9 Phase III Randomized Study of Hypericum Perforatum (St. John's Wort) Combined With Docetaxel in Patients With Unresectable Solid Tumors Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
10 Phase II Study of Imatinib (Glivec) Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Overexpressing KIT Unknown status NCT00180921 Phase 2 Imatinib
11 Combined Treatment of Adenoid Cystic Carcinoma With Cetuximab and IMRT Plus C12 Heavy Ion Boost - ACCEPT - (ACC, Erbitux, and Particle Therapy); Phase I/II Feasibility Study Unknown status NCT01192087 Phase 1, Phase 2 Cetuximab
12 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
13 Phase II Study On Gemcitabine In Recurrent Or Metastatic Adenoid Cystic Carcinoma Of The Head And Neck Completed NCT00017498 Phase 2 gemcitabine hydrochloride
14 A Phase 2 Study of GW572016 in Recurrent and/or Metastatic Adenoid Cystic Carcinoma, and Other EGFR-and/or erbB2-expressing Malignant Tumors of the Salivary Glands Completed NCT00095563 Phase 2 lapatinib ditosylate
15 Phase II Study of TKI258 (Dovitinib) Monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma Completed NCT01417143 Phase 2 TKI258 (Dovitinib):
16 A Phase II Study of DOVitinib in REcurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (DOVE) Completed NCT01678105 Phase 2 Dovitinib
17 Phase II Study of RAD001monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma Completed NCT01152840 Phase 2 RAD001
18 Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Head and Neck Adenoid Cystic Carcinoma Completed NCT00581360 Phase 2 doxorubicin and bortezomib
19 A Phase II Study of Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Completed NCT01558661 Phase 2 AG-013736 (AXITINIB)
20 A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Completed NCT01604772 Phase 2 Akt Inhibitor MK2206
21 A Phase 2 Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT00886132 Phase 2 Sunitinib
22 A Phase II Pilot Study of Dovitinib (TKI258) in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Completed NCT01524692 Phase 2 Dovitinib (TKI258)
23 A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Subjects With Locally Advanced, Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) Completed NCT01175980 Phase 2 Vorinostat
24 Phase II Trial of PS-341 (NSC 681239) Followed by the Addition of Doxorubicin at Progression in Advanced Adenoid Cystic Carcinoma of the Head and Neck Completed NCT00077428 Phase 2 bortezomib;doxorubicin hydrochloride
25 Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors Completed NCT00859937 Phase 2 Dasatinib
26 Herceptin In Patients With Advanced or Metastatic Salivary Gland Carcinomas Completed NCT00004163 Phase 2 Trastuzumab
27 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
28 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
29 Gemcitabine for Advanced Salivary Cancer: A Phase II Study Completed NCT00003744 Phase 2 gemcitabine
30 A Phase 2 Study Of Imatinib Mesylate In Adenoid Cystic, Lymphoepithelioma-Like And Myoepithelial Salivary Gland Carcinomas Completed NCT00045669 Phase 2 imatinib mesylate
31 A Phase II Study of Cisplatin and Gemcitabine in Patients With Locally Advanced/Recurrent or Metastatic Malignant Salivary Gland Tumors Completed NCT00079079 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride
32 A Phase II Trial of the HIV Protease Inhibitor Nelfinavir in Patients With Recurrent Symptomatic Adenoid Cystic Cancers of the Head and Neck Completed NCT01065844 Phase 2 Nelfinavir
33 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
34 A Phase I Study of Concomitant Chemoradiotherapy With 776C85, 5-FU and Hydroxyurea for Patients With Poor Prognosis Oral Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
35 Treatment of Relapsed or Metastatic Head and Neck Carcinomas With Oxaliplatin and Capecitabine Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
36 A Phase II Study of Gemcitabine in Combination With Doxorubicin for Patients With Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
37 High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
38 A Study of Population Pharmacokinetics of Docetaxel (Taxotere) in Caucasian and African-American Cancer Patients Completed NCT00003565 Phase 2 docetaxel
39 A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies Completed NCT00003103 Phase 1, Phase 2 docetaxel
40 Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
41 Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety Recruiting NCT02883374 Phase 2 Chidamide
42 Chidamide Combined With Cisplatin in Recurrent or Metastatic Head and Neck Adenoid Cystic Carcinoma: A Prospective, Open-label, Phase II Study of a Single Center Recruiting NCT03639168 Phase 2 Chidamide combined with cisplatin
43 A Phase 2, Open-Label, Single-Arm, Multi-Center Study Of AL101 (BMS-906024) In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations Recruiting NCT03691207 Phase 2 AL101
44 A Phase II Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma Recruiting NCT03999684 Phase 2 Tretinoin
45 A Phase II Randomized Trial of Efficacy and Safety of Particle Therapy With or Without Apatinib as Induction Therapy for Treatment of Head and Neck Adenoid Cystic Carcinoma Recruiting NCT02942693 Phase 2 Apatinib
46 A Phase 2 Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma (ACC) Recruiting NCT03990571 Phase 2 Avelumab;Axitinib
47 A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study With Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway Recruiting NCT03422679 Phase 1, Phase 2 CB-103
48 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
49 The Efficacy of Cabozantinib in Advanced SAlivary Gland Cancer Patients, a Phase II Clinical Trial Recruiting NCT03729297 Phase 2 Cabozantinib
50 Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma of All Anatomic Sites of Origin and Non-adenoid Cystic Carcinoma Malignant Tumors of the Salivary Gland Recruiting NCT03146650 Phase 2

Search NIH Clinical Center for Adenoid Cystic Carcinoma

Cochrane evidence based reviews: carcinoma, adenoid cystic

Genetic Tests for Adenoid Cystic Carcinoma

Anatomical Context for Adenoid Cystic Carcinoma

MalaCards organs/tissues related to Adenoid Cystic Carcinoma:

41
Salivary Gland, Breast, Lung, Trachea, Cervix, Lymph Node, Brain

Publications for Adenoid Cystic Carcinoma

Articles related to Adenoid Cystic Carcinoma:

(show top 50) (show all 4360)
# Title Authors PMID Year
1
Genetic Characterization of Adenoid Cystic Carcinoma of the Minor Salivary Glands: A Potential Familial Occurrence in First-Degree Relatives. 38 6
28210977 2017
2
C-kit gene mutations in adenoid cystic carcinoma are rare. 9 38
20514080 2010
3
Expression of c-kit and Slug correlates with invasion and metastasis of salivary adenoid cystic carcinoma. 9 38
20219417 2010
4
Prognostic value of quantitative p63 immunostaining in adenoid cystic carcinoma of salivary gland assessed by computerized image analysis. 9 38
19877114 2010
5
Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). 9 38
19574086 2009
6
Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. 9 38
19617878 2009
7
Differential expression of galectin-3, beta-catenin, and cyclin D1 in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands. 9 38
19659475 2009
8
Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. 9 38
18983466 2008
9
Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors. 9 38
17936671 2008
10
Effect of exogenous bFGF on the proliferation of human adenoid cystic carcinoma ACC-2 cells. 9 38
18481005 2008
11
[Effects of basic fibroblast growth factor on the proliferation of human salivary adenoid cystic carcinoma cell line ACC-2 and extracellular signal-regulated kinase, Cyclin D1, p2waf/cip1 signaling pathway]. 9 38
18605443 2008
12
[Prognostic value of immunohistochemistry in salivary gland cancer]. 9 38
18214402 2008
13
Hierarchical cluster analysis of myoepithelial/basal cell markers in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. 9 38
18084258 2008
14
Primary adenoid cystic carcinoma of the lung: absence of KIT mutations. 9 38
17932891 2007
15
Expression of neural cell adhesion molecule in salivary adenoid cystic carcinoma and its correlation with perineural invasion. 9 38
17982624 2007
16
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. 9 38
17761983 2007
17
[Expression and significance of E-cadherin in adenoid cystic carcinoma of the salivary glands]. 9 38
17927866 2007
18
Galectin-3 immunoprofile in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands. 9 38
16996782 2007
19
Relative frequency of intra-oral minor salivary gland tumors: a study of 380 cases from northern California and comparison to reports from other parts of the world. 9 38
17391298 2007
20
[Effect of mechanical stimulation on the expression of E-cadherin/cateninin complex in salivary adenoid cystic carcinoma]. 9 38
17375572 2007
21
A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. 9 38
16757202 2007
22
Application of alpha-smooth muscle actin and c-kit in the differential diagnosis of adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. 9 38
16807072 2007
23
Adenoid cystic carcinoma of the buccal vestibule: A case report and review of the literature. 9 38
16996786 2006
24
Immunophenotypic overlap between adenoid cystic carcinoma and collagenous spherulosis of the breast: potential diagnostic pitfalls using myoepithelial markers. 9 38
16810311 2006
25
[Expression of Pin1, beta-catenin and cyclin D1 in salivary adenoid cystic carcinoma and its significance]. 9 38
17129455 2006
26
Aberrant expression of beta-catenin, Pin1 and cylin D1 in salivary adenoid cystic carcinoma: relation to tumor proliferation and metastasis. 9 38
16865250 2006
27
Knockdown of Sox4 expression by RNAi induces apoptosis in ACC3 cells. 9 38
16636670 2006
28
Protein expression profiling identifies maspin and stathmin as potential biomarkers of adenoid cystic carcinoma of the salivary glands. 9 38
16094606 2006
29
Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis. 9 38
16184379 2006
30
Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. 9 38
16140564 2006
31
KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. 9 38
16258515 2005
32
Clinical prognostic factors in malignant parotid gland tumors. 9 38
16274796 2005
33
Induction of apoptosis in human salivary gland tumor cells by anti-NCAM antibody. 9 38
16211277 2005
34
Differential KIT expression in histological subtypes of adenoid cystic carcinoma (ACC) of the salivary gland. 9 38
16054424 2005
35
Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. 9 38
15846389 2005
36
Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. 9 38
16243805 2005
37
KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. 9 38
16082245 2005
38
Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. 9 38
16135502 2005
39
Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. 9 38
15959912 2005
40
[Expression and significance of cyclin D1 in human adenoid cystic carcinoma]. 9 38
16078452 2005
41
Cylindroma (dermal analog tumor) of the breast: a comparison with cylindroma of the skin and adenoid cystic carcinoma of the breast. 9 38
15899777 2005
42
Expression of IgSF in salivary adenoid cystic carcinoma and its relationship with invasion and metastasis. 9 38
15817073 2005
43
Adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of minor salivary glands: a comparative immunohistochemical study using the epithelial membrane and carcinoembryonic antibodies. 9 38
15888109 2005
44
Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. 9 38
15863127 2005
45
Expression of beta-catenin, E-cadherin and cyclin D1 in adenoid cystic carcinoma of the salivary gland. 9 38
15943036 2005
46
"Parapharyngeal space" tumors: a cytopathological study of 24 cases on fine-needle aspiration. 9 38
15584054 2005
47
P53, bcl-2 and Ki-67 expression in adenoid cystic carcinoma of the palate. A clinico-pathologic study of 21 cases with long-term follow-up. 9 38
15792122 2005
48
Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. 9 38
15659505 2005
49
Lip cancer experience in Mexico. An 11-year retrospective study. 9 38
15509490 2004
50
Cyclin D1 expression does not effect cell proliferation in adenoid cystic carcinoma of the salivary gland. 9 38
14714130 2004

Variations for Adenoid Cystic Carcinoma

ClinVar genetic disease variations for Adenoid Cystic Carcinoma:

6 (show top 50) (show all 59)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 MYBL1 ; NFIB t(8;9)(q13.1;p22.3) Translocation Pathogenic 8:67501293-67501294 :0-0
2 MYB ; NFIB t(6;9)(q23.3;p22.3) Translocation Pathogenic 6:135522688-135522689 :0-0
3 MYB ; NFIB t(6;9)(q23.3;p22.3) Translocation Pathogenic 6:135515857-135515858 :0-0
4 MYB ; NFIB t(6;9)(q23.3;p22.3) Translocation Pathogenic 6:135516358-135516359 :0-0
5 MYB ; NFIB t(6;9)(q23.3;p22.3) Translocation Pathogenic 6:135516423-135516424 :0-0
6 KRAS NM_004985.5(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 12:25398285-25398285 12:25245351-25245351
7 HRAS NM_005343.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
8 HRAS NM_005343.4(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 11:534288-534288 11:534288-534288
9 HRAS NM_005343.4(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
10 PIK3CA NM_006218.4(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic rs121913272 3:178927980-178927980 3:179210192-179210192
11 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893
12 JAK3 NM_000215.3(JAK3): c.1765G> A (p.Gly589Ser) single nucleotide variant Pathogenic rs886039394 19:17947959-17947959 19:17837150-17837150
13 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 17:7578479-7578479 17:7675161-7675161
14 IDH1 NM_005896.3(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 2:209113112-209113112 2:208248388-208248388
15 PIK3CA NM_006218.4(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 3:178952074-178952074 3:179234286-179234286
16 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893
17 IDH1 NM_005896.3(IDH1): c.395G> T (p.Arg132Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 2:209113112-209113112 2:208248388-208248388
18 IDH1 NM_005896.3(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 2:209113113-209113113 2:208248389-208248389
19 IDH1 NM_005896.3(IDH1): c.394C> G (p.Arg132Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 2:209113113-209113113 2:208248389-208248389
20 IDH1 NM_005896.3(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 2:209113113-209113113 2:208248389-208248389
21 PIK3CA NM_006218.4(PIK3CA): c.1035T> A (p.Asn345Lys) single nucleotide variant Likely pathogenic rs121913284 3:178921553-178921553 3:179203765-179203765
22 CREBBP NM_001079846.1(CREBBP): c.4223G> T (p.Arg1408Leu) single nucleotide variant Likely pathogenic rs1057519884 16:3788617-3788617 16:3738616-3738616
23 CREBBP NM_001079846.1(CREBBP): c.4223G> A (p.Arg1408His) single nucleotide variant Likely pathogenic rs1057519884 16:3788617-3788617 16:3738616-3738616
24 CREBBP NM_001079846.1(CREBBP): c.4222C> G (p.Arg1408Gly) single nucleotide variant Likely pathogenic rs398124146 16:3788618-3788618 16:3738617-3738617
25 FBXW7 NM_018315.5(FBXW7): c.1153C> T (p.Arg385Cys) single nucleotide variant Likely pathogenic rs867384286 4:153249385-153249385 4:152328233-152328233
26 FBXW7 NM_018315.5(FBXW7): c.1154G> A (p.Arg385His) single nucleotide variant Likely pathogenic rs1057519895 4:153249384-153249384 4:152328232-152328232
27 FBXW7 NM_018315.5(FBXW7): c.1154G> C (p.Arg385Pro) single nucleotide variant Likely pathogenic rs1057519895 4:153249384-153249384 4:152328232-152328232
28 FBXW7 NM_018315.5(FBXW7): c.1154G> T (p.Arg385Leu) single nucleotide variant Likely pathogenic rs1057519895 4:153249384-153249384 4:152328232-152328232
29 FBXW7 NM_018315.5(FBXW7): c.1153C> G (p.Arg385Gly) single nucleotide variant Likely pathogenic rs867384286 4:153249385-153249385 4:152328233-152328233
30 PIK3CA NM_006218.4(PIK3CA): c.1258T> G (p.Cys420Gly) single nucleotide variant Likely pathogenic rs121913272 3:178927980-178927980 3:179210192-179210192
31 PIK3CA NM_006218.4(PIK3CA): c.1034A> T (p.Asn345Ile) single nucleotide variant Likely pathogenic rs1057519938 3:178921552-178921552 3:179203764-179203764
32 PIK3CA NM_006218.4(PIK3CA): c.3127A> G (p.Met1043Val) single nucleotide variant Likely pathogenic rs1057519936 3:178952072-178952072 3:179234284-179234284
33 PIK3CA NM_006218.4(PIK3CA): c.3128T> C (p.Met1043Thr) single nucleotide variant Likely pathogenic rs1057519937 3:178952073-178952073 3:179234285-179234285
34 PIK3CA NM_006218.4(PIK3CA): c.3127A> T (p.Met1043Leu) single nucleotide variant Likely pathogenic rs1057519936 3:178952072-178952072 3:179234284-179234284
35 PIK3CA NM_006218.4(PIK3CA): c.1034A> C (p.Asn345Thr) single nucleotide variant Likely pathogenic rs1057519938 3:178921552-178921552 3:179203764-179203764
36 PIK3CA NM_006218.4(PIK3CA): c.1033A> C (p.Asn345His) single nucleotide variant Likely pathogenic rs1057519939 3:178921551-178921551 3:179203763-179203763
37 SF3B1 NM_012433.3(SF3B1): c.1874G> A (p.Arg625His) single nucleotide variant Likely pathogenic rs1057519961 2:198267483-198267483 2:197402759-197402759
38 SF3B1 NM_012433.3(SF3B1): c.1873C> T (p.Arg625Cys) single nucleotide variant Likely pathogenic rs775623976 2:198267484-198267484 2:197402760-197402760
39 SF3B1 NM_012433.3(SF3B1): c.1873C> G (p.Arg625Gly) single nucleotide variant Likely pathogenic rs775623976 2:198267484-198267484 2:197402760-197402760
40 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 17:7578479-7578479 17:7675161-7675161
41 TP53 NM_000546.5(TP53): c.638G> T (p.Arg213Leu) single nucleotide variant Likely pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893
42 TP53 NM_000546.5(TP53): c.637C> G (p.Arg213Gly) single nucleotide variant Likely pathogenic rs397516436 17:7578212-7578212 17:7674894-7674894
43 BCOR NM_001123383.1(BCOR): c.398_399insAC (p.Ala134fs) insertion Likely pathogenic rs1555919960 X:39934200-39934201 X:40074947-40074948
44 NOTCH1 NM_017617.5(NOTCH1): c.4045_4052del (p.Ala1349fs) deletion Likely pathogenic rs1554728034 9:139400296-139400303 9:136505844-136505851
45 NOTCH1 NM_017617.5(NOTCH1): c.2825G> A (p.Cys942Tyr) single nucleotide variant Likely pathogenic rs1554728658 9:139404329-139404329 9:136509877-136509877
46 ARID2 NM_152641.4(ARID2): c.2989C> T (p.Gln997Ter) single nucleotide variant Likely pathogenic rs1555155110 12:46244895-46244895 12:45851112-45851112
47 BCOR NM_001123383.1(BCOR): c.4685_4700del (p.Gly1562fs) deletion Likely pathogenic rs1555913337 X:39913526-39913541 X:40054273-40054288
48 BCOR NM_001123383.1(BCOR): c.3961G> T (p.Glu1321Ter) single nucleotide variant Likely pathogenic rs780712297 X:39922109-39922109 X:40062856-40062856
49 CREBBP NM_001079846.1(CREBBP): c.4222C> T (p.Arg1408Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs398124146 16:3788618-3788618 16:3738617-3738617
50 FGFR2 NM_000141.4(FGFR2): c.1144T> C (p.Cys382Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs121913474 10:123274774-123274774 10:121515260-121515260

Cosmic variations for Adenoid Cystic Carcinoma:

9 (show top 50) (show all 15331)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1659071 WASF2 salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.15G>T p.T5T 1:27428876-27428876 16
2 COSM6939530 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 16
3 COSM6939527 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2684T>A p.V895D 9:132897552-132897552 16
4 COSM1659031 TRPV5 salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.554A>G p.H185R 7:142929054-142929054 16
5 COSM1658989 TP53BP1 salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.3854C>G p.T1285S 15:43422086-43422086 16
6 COSM43878 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.427G>A p.V143M 17:7675185-7675185 16
7 COSM10777 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.715A>G p.N239D 17:7674248-7674248 16
8 COSM1659046 THRA salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.1162C>T p.R388W 17:40093071-40093071 16
9 COSM6935085 TENT5C salivary gland,minor,carcinoma,adenoid cystic carcinoma c.833T>A p.F278Y 1:117623701-117623701 16
10 COSM6939534 STAG2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2405T>G p.I802S 23:124071195-124071195 16
11 COSM6939532 SOX9 salivary gland,major,carcinoma,adenoid cystic carcinoma c.1457T>A p.V486D 17:72124314-72124314 16
12 COSM6939526 SMO salivary gland,major,carcinoma,adenoid cystic carcinoma c.385G>C p.V129L 7:129203437-129203437 16
13 COSM1658912 SLC26A2 salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.1474C>T p.R492W 5:149981067-149981067 16
14 COSM6915408 SF3B1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.3254C>T p.A1085V 2:197397997-197397997 16
15 COSM6910358 SETD2 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.4870C>T p.Q1624* 3:47057405-47057405 16
16 COSM41699 RUNX1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.958C>T p.R320* 21:34799310-34799310 16
17 COSM6928612 RPTOR salivary gland,minor,carcinoma,adenoid cystic carcinoma c.734C>T p.A245V 17:80754089-80754089 16
18 COSM1659033 RNF38 salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.623A>G p.H208R 9:36357890-36357890 16
19 COSM6961503 RIT1 salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.235C>G p.Q79E 1:155904733-155904733 16
20 COSM1644939 RB1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.1817A>G p.Y606C 13:48456206-48456206 16
21 COSM6913929 RASA1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2603+2T>A p.? 5:87379852-87379852 16
22 COSM6910894 RASA1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.3026T>G p.L1009R 5:87389493-87389493 16
23 COSM6910364 RARA salivary gland,minor,carcinoma,adenoid cystic carcinoma c.691C>G p.L231V 17:40352391-40352391 16
24 COSM1110409 PTPRD salivary gland,major,carcinoma,adenoid cystic carcinoma c.5473G>C p.G1825R 9:8331643-8331643 16
25 COSM3219585 PTPRD salivary gland,major,carcinoma,adenoid cystic carcinoma c.3542G>A p.R1181H 9:8465638-8465638 16
26 COSM5046 PTEN salivary gland,major,carcinoma,adenoid cystic carcinoma c.764T>C p.V255A 10:87957982-87957982 16
27 COSM51211 PPP2R1A salivary gland,major,carcinoma,adenoid cystic carcinoma c.547C>T p.R183W 19:52212729-52212729 16
28 COSM6935088 PIK3CG salivary gland,minor,carcinoma,adenoid cystic carcinoma c.2951C>A p.P984Q 7:106886213-106886213 16
29 COSM757 PIK3CA salivary gland,minor,carcinoma,adenoid cystic carcinoma c.1258T>C p.C420R 3:179210192-179210192 16
30 COSM6960739 PIK3C2G salivary gland,major,carcinoma,adenoid cystic carcinoma c.1852C>G p.P618A 12:18381860-18381860 16
31 COSM6939528 PGR salivary gland,major,carcinoma,adenoid cystic carcinoma c.1604C>G p.P535R 11:101127467-101127467 16
32 COSM6916607 NTRK2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2336T>C p.I779T 9:85021256-85021256 16
33 COSM6959277 NTRK2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2158A>T p.T720S 9:84955503-84955503 16
34 COSM6909937 NOTCH1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.973A>G p.N325D 9:136518717-136518717 16
35 COSM6916910 NOTCH1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.403+1G>C p.? 9:136523716-136523716 16
36 COSM13044 NOTCH1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.5101G>C p.A1701P 9:136503248-136503248 16
37 COSM3929943 NOTCH1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.1367G>A p.C456Y 9:136517826-136517826 16
38 COSM13081 NOTCH1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.7400C>A p.S2467* 9:136496339-136496339 16
39 COSM6910892 MYCN salivary gland,major,carcinoma,adenoid cystic carcinoma c.1336A>G p.K446E 2:15946038-15946038 16
40 COSM6911643 MET salivary gland,major,carcinoma,adenoid cystic carcinoma c.1249C>G p.R417G 7:116731716-116731716 16
41 COSM1659036 MELK salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.817T>C p.W273R 9:36633183-36633183 16
42 COSM6910361 MAX salivary gland,minor,carcinoma,adenoid cystic carcinoma c.295+1G>A p.? 14:65077912-65077912 16
43 COSM1659003 MAP2 salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.31G>T p.A11S 2:209653201-209653201 16
44 COSM51382 KRAS salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.50G>A p.S17N 12:25245335-25245335 16
45 COSM4042348 KMT2D salivary gland,minor,carcinoma,adenoid cystic carcinoma c.12640C>T p.R4214* 12:49031255-49031255 16
46 COSM6927891 KMT2D salivary gland,major,carcinoma,adenoid cystic carcinoma c.3587G>A p.W1196* 12:49046621-49046621 16
47 COSM6909196 KMT2D salivary gland,major,carcinoma,adenoid cystic carcinoma c.9308C>A p.S3103* 12:49037238-49037238 16
48 COSM51381 KIT salivary gland,face,carcinoma,adenoid cystic carcinoma c.2386A>G p.R796G 4:54733094-54733094 16
49 COSM5609233 KDR salivary gland,major,carcinoma,adenoid cystic carcinoma c.2524C>T p.R842C 4:55097752-55097752 16
50 COSM1658780 KDM6A salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.2833-1G>A p.? 23:45078399-45078399 16

Copy number variations for Adenoid Cystic Carcinoma from CNVD:

7 (show top 50) (show all 209)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13805 1 1 61300000 Deletion Adenoid cystic carcinoma
2 31809 1 31200000 32688000 Loss BAI2 Adenoid cystic carcinoma
3 31810 1 31200000 32688000 Loss EIF3S2 Adenoid cystic carcinoma
4 31811 1 31200000 32688000 Loss FABP3 Adenoid cystic carcinoma
5 31812 1 31200000 32688000 Loss HDAC1 Adenoid cystic carcinoma
6 31813 1 31200000 32688000 Loss IQCC Adenoid cystic carcinoma
7 31814 1 31200000 32688000 Loss KHDRBS1 Adenoid cystic carcinoma
8 31815 1 31200000 32688000 Loss LCK Adenoid cystic carcinoma
9 31816 1 31200000 32688000 Loss MARCKSL1 Adenoid cystic carcinoma
10 31817 1 31200000 32688000 Loss PTP4A2 Adenoid cystic carcinoma
11 31818 1 31200000 32688000 Loss PUM1 Adenoid cystic carcinoma
12 31819 1 31200000 32688000 Loss RBBP4 Adenoid cystic carcinoma
13 31820 1 31200000 32688000 Loss SERINC2 Adenoid cystic carcinoma
14 31821 1 31200000 32688000 Loss TXLNA Adenoid cystic carcinoma
15 33928 1 50618000 52179000 Loss CDKN2C Adenoid cystic carcinoma
16 33929 1 50618000 52179000 Loss EPS15 Adenoid cystic carcinoma
17 33930 1 50618000 52179000 Loss FAF1 Adenoid cystic carcinoma
18 33931 1 50618000 52179000 Loss NRD1 Adenoid cystic carcinoma
19 33932 1 50618000 52179000 Loss RAB3B Adenoid cystic carcinoma
20 33933 1 50618000 52179000 Loss RNF11 Adenoid cystic carcinoma
21 50143 11 114500000 121200000 Deletion Adenoid cystic carcinoma
22 50146 11 114500000 121200000 Gain Salivary gland adenoid cystic carcinoma
23 58545 11 68400000 70400000 Deletion Adenoid cystic carcinoma
24 58546 11 68400000 70400000 Gain Salivary gland adenoid cystic carcinoma
25 61970 12 103800000 109000000 LOH Adenoid cystic carcinoma
26 64283 12 125900000 133851895 LOH Adenoid cystic carcinoma
27 67068 12 35800000 133851895 Loss Adenoid cystic carcinoma
28 67236 12 38200000 58100000 Deletion Adenoid cystic carcinoma
29 67639 12 43743000 50676000 Loss ACVR1B Adenoid cystic carcinoma
30 67640 12 43743000 50676000 Loss ACVRL1 Adenoid cystic carcinoma
31 67641 12 43743000 50676000 Loss ADCY6 Adenoid cystic carcinoma
32 67642 12 43743000 50676000 Loss AMIGO2 Adenoid cystic carcinoma
33 67643 12 43743000 50676000 Loss ANP32D Adenoid cystic carcinoma
34 67644 12 43743000 50676000 Loss ARF3 Adenoid cystic carcinoma
35 67645 12 43743000 50676000 Loss ATF1 Adenoid cystic carcinoma
36 67646 12 43743000 50676000 Loss CCNT1 Adenoid cystic carcinoma
37 67647 12 43743000 50676000 Loss COL2A1 Adenoid cystic carcinoma
38 67648 12 43743000 50676000 Loss DDX23 Adenoid cystic carcinoma
39 67649 12 43743000 50676000 Loss FAIM2 Adenoid cystic carcinoma
40 67650 12 43743000 50676000 Loss HDAC7A Adenoid cystic carcinoma
41 67651 12 43743000 50676000 Loss LALBA Adenoid cystic carcinoma
42 67652 12 43743000 50676000 Loss LETMD1 Adenoid cystic carcinoma
43 67653 12 43743000 50676000 Loss LIMA1 Adenoid cystic carcinoma
44 67654 12 43743000 50676000 Loss MLL2 Adenoid cystic carcinoma
45 67655 12 43743000 50676000 Loss PFKM Adenoid cystic carcinoma
46 67656 12 43743000 50676000 Loss PLEKHA9 Adenoid cystic carcinoma
47 67657 12 43743000 50676000 Loss PRKAG1 Adenoid cystic carcinoma
48 67658 12 43743000 50676000 Loss RACGAP1 Adenoid cystic carcinoma
49 67659 12 43743000 50676000 Loss RAPGEF3 Adenoid cystic carcinoma
50 67660 12 43743000 50676000 Loss RHEBL1 Adenoid cystic carcinoma

Expression for Adenoid Cystic Carcinoma

Search GEO for disease gene expression data for Adenoid Cystic Carcinoma.

Pathways for Adenoid Cystic Carcinoma

Pathways related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 129)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.29 TP53 PTEN PIK3CA NOTCH1 KRAS KIT
2
Show member pathways
14.13 TP53 SERPINA3 PTEN PIK3CA KRAS KIT
3
Show member pathways
13.96 TP53 PTEN NOTCH1 KRAS KIT JAK3
4
Show member pathways
13.82 TP53 NOTCH1 KRAS KIT JAK3 HRAS
5
Show member pathways
13.82 PIK3CA NOTCH1 KRAS KIT IDH1 HRAS
6
Show member pathways
13.64 TP53 PIK3CA KRAS KIT JAK3 HRAS
7
Show member pathways
13.62 PIK3CA NOTCH1 KRT7 KRT14 KRAS KIT
8
Show member pathways
13.58 TP53 PTEN PIK3CA KRAS KIT HRAS
9
Show member pathways
13.53 TP53 PTEN KRAS KIT JAK3 HRAS
10
Show member pathways
13.49 TP53 PIK3CA KRAS KIT JAK3 HRAS
11
Show member pathways
13.44 TP53 SERPINA3 PIK3CA MYB KRAS JAK3
12
Show member pathways
13.4 PTEN NOTCH1 KRAS KIT HRAS ERBB2
13
Show member pathways
13.34 TP53 PTEN KRAS JAK3 HRAS ERBB2
14
Show member pathways
13.16 TP53 PTEN KRAS KIT HRAS AKT1
15
Show member pathways
13.09 TP53 PTEN PIK3CA KRAS HRAS CCND1
16
Show member pathways
13.05 TP53 PTEN PIK3CA KRAS HRAS AKT1
17
Show member pathways
13.03 PTEN PIK3CA KRAS HRAS ERBB2 CCND1
18
Show member pathways
13.02 TP53 PIK3CA KRAS KIT HRAS AKT1
19
Show member pathways
13.02 PTEN PIK3CA KRAS HRAS ERBB2 AKT1
20
Show member pathways
13 PIK3CA KRAS JAK3 HRAS CCND1 AKT1
21
Show member pathways
13 PTEN PIK3CA KRAS JAK3 HRAS ERBB2
22
Show member pathways
12.96 TP53 PTEN PIK3CA KRAS KIT HRAS
23
Show member pathways
12.91 PTEN PIK3CA KRAS JAK3 HRAS CCND1
24
Show member pathways
12.9 TP53 PIK3CA KRAS HRAS AKT1
25 12.9 TP53 KRAS KIT HRAS ERBB2 AKT1
26
Show member pathways
12.87 TP53 PTEN PIK3CA NOTCH1 MYB KRAS
27
Show member pathways
12.84 TP53 PTEN PIK3CA KRAS HRAS ERBB2
28
Show member pathways
12.84 TP53 PTEN PIK3CA KRAS KIT HRAS
29
Show member pathways
12.83 PIK3CA KRAS KIT HRAS AKT1
30 12.83 TP53 PTEN PIK3CA NOTCH1 KRAS KIT
31
Show member pathways
12.81 PTEN PIK3CA KRAS HRAS CCND1 AKT1
32
Show member pathways
12.78 TP53 KRAS JAK3 HRAS AKT1
33
Show member pathways
12.73 TP53 PIK3CA KRAS HRAS ERBB2 AKT1
34
Show member pathways
12.72 TP53 PIK3CA KRAS HRAS ERBB2 CCND1
35
Show member pathways
12.7 PTEN PIK3CA KRAS HRAS AKT1
36
Show member pathways
12.7 TP53 PTEN PIK3CA NOTCH1 KRAS JAK3
37
Show member pathways
12.64 PIK3CA KRAS HRAS AKT1
38
Show member pathways
12.64 TP53 PTEN PIK3CA KRAS HRAS ERBB2
39 12.63 TP53 PTEN PIK3CA NOTCH1 KRAS HRAS
40
Show member pathways
12.62 PTEN PIK3CA KRAS HRAS ERBB2 CCND1
41
Show member pathways
12.57 TP53 PIK3CA HRAS CCND1 AKT1
42
Show member pathways
12.57 TP53 PIK3CA KRAS HRAS ERBB2 AKT1
43
Show member pathways
12.56 PIK3CA KRAS HRAS AKT1
44
Show member pathways
12.56 TP53 SMARCA2 PTEN PIK3CA NOTCH1 KRAS
45
Show member pathways
12.54 PIK3CA KRAS KIT HRAS AKT1
46
Show member pathways
12.54 PIK3CA KRAS JAK3 HRAS AKT1
47
Show member pathways
12.54 PTEN PIK3CA KRAS HRAS AKT1
48
Show member pathways
12.54 PIK3CA KRAS JAK3 HRAS CCND1 AKT1
49
Show member pathways
12.51 TP53 PTEN PIK3CA JAK3 HRAS CCND1
50
Show member pathways
12.49 PIK3CA KRAS KIT HRAS ERBB2

GO Terms for Adenoid Cystic Carcinoma

Cellular components related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.86 TP53 PTEN PIK3CA NOTCH1 KRT7 KRT14
2 cytosol GO:0005829 9.47 TP53 PTEN PIK3CA NOTCH1 KRT7 KRT14
3 nucleus GO:0005634 10 TP53 SMARCA2 SERPINA3 PTEN NOTCH1 NFIB

Biological processes related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.93 NOTCH1 HRAS FBXW7 AKT1
2 negative regulation of cell proliferation GO:0008285 9.93 TP53 SMARCA2 PTEN NOTCH1 NFIB HRAS
3 MAPK cascade GO:0000165 9.83 KRAS KIT JAK3 HRAS ERBB2
4 positive regulation of cell proliferation GO:0008284 9.8 PTEN NOTCH1 KRAS KIT HRAS CCND1
5 Ras protein signal transduction GO:0007265 9.77 TP53 KRAS HRAS
6 positive regulation of protein phosphorylation GO:0001934 9.77 KRAS HRAS ERBB2 CCND1 AKT1
7 positive regulation of epithelial cell proliferation GO:0050679 9.75 NOTCH1 HRAS ERBB2
8 cell proliferation GO:0008283 9.72 TP53 PTEN AKT1
9 liver development GO:0001889 9.71 PIK3CA NOTCH1 KRAS CCND1
10 protein kinase B signaling GO:0043491 9.69 PTEN PIK3CA AKT1
11 phosphatidylinositol 3-kinase signaling GO:0014065 9.65 PIK3CA ERBB2 AKT1
12 anoikis GO:0043276 9.62 PIK3CA AKT1
13 somatic stem cell division GO:0048103 9.62 NOTCH1 KIT
14 positive regulation of MAP kinase activity GO:0043406 9.62 KRAS KIT HRAS ERBB2
15 negative regulation of cell size GO:0045792 9.61 PTEN AKT1
16 mitotic G1 DNA damage checkpoint GO:0031571 9.59 TP53 CCND1
17 enzyme linked receptor protein signaling pathway GO:0007167 9.58 JAK3 ERBB2
18 response to isolation stress GO:0035900 9.56 KRAS HRAS
19 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.55 PTEN NOTCH1 KIT HRAS FBXW7
20 cellular response to decreased oxygen levels GO:0036294 9.52 PTEN AKT1
21 cytokine-mediated signaling pathway GO:0019221 9.5 TP53 PIK3CA KRAS KIT JAK3 CCND1
22 response to UV-A GO:0070141 9.49 CCND1 AKT1
23 positive regulation of gene expression GO:0010628 9.23 TP53 PTEN NOTCH1 KRAS KIT HRAS
24 positive regulation of transcription by RNA polymerase II GO:0045944 10.11 TP53 SMARCA2 NOTCH1 NFIB MYB HRAS
25 negative regulation of transcription by RNA polymerase II GO:0000122 10.08 TP53 SMARCA2 NOTCH1 NFIB MYB CCND1
26 protein phosphorylation GO:0006468 10.01 PIK3CA KIT JAK3 ERBB2 CCND1 AKT1

Molecular functions related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 TP53 SMARCA2 SERPINA3 PTEN PIK3CA NOTCH1
2 protein kinase binding GO:0019901 9.77 TP53 PTEN CYLD CCND1 AKT1
3 kinase activity GO:0016301 9.73 PIK3CA KIT JAK3 ERBB2 CCND1 AKT1
4 protein phosphatase binding GO:0019903 9.58 TP53 JAK3 ERBB2
5 enzyme binding GO:0019899 9.55 TP53 PTEN NOTCH1 CCND1 AKT1
6 nucleotide binding GO:0000166 9.1 SMARCA2 KRAS KIT JAK3 HRAS ERBB2
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.02 PIK3CA

Sources for Adenoid Cystic Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....